



FutureGen
INDUSTRIES CORP.

LITT-TSXV

Identifying and Investing
in the Next Generation of
Biotech, AI, Robotics,
Quantum, and Defence
Innovators

Forward Looking Statements & Disclaimer

Forward looking information. This presentation contains "forward looking information" within the meaning of applicable Canadian securities legislation. Wherever possible, words such as "plans", "expects", or "does not expect", "budget", "scheduled", "estimates", "forecasts", "anticipate" or "does not anticipate", "believe", "intend" and similar expressions or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved, have been used to identify forward looking information. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of FutureGen Industries Corp. (formerly Right Season Investments Corp.) ("FutureGen" or the "Company") to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Although FutureGen has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward looking statements are based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. Management believes that the assumptions and expectations reflected in such forward-looking statements are reasonable. Market data disclaimer. This presentation includes market and industry data that has been obtained from third party sources including publications from various industries, and where appropriate, certain numbers, including dollar amounts, have been rounded out by us to avoid lengthy numbers. We believe that this industry data is accurate and that its estimates and assumptions are reasonable; however, there are no assurances as to the accuracy or completeness of this data. Third party sources generally state that the information contained therein has been obtained from sources believed to be reliable; however, there are no assurances as to the accuracy or completeness of included information. Although the data is believed to be reliable, we have not independently verified any of the data from third party sources referred to in this presentation or ascertained the underlying economic assumptions relied upon by such sources.

This presentation is provided for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities of FutureGen in any jurisdiction. Any offering of securities will only be made pursuant to a prospectus filed with applicable Canadian securities regulators or in reliance on available exemptions from prospectus requirements under National Instrument 45-106 Prospectus Exemptions. The TSX Venture Exchange ("TSXV") has not reviewed or approved the contents of this presentation. No securities regulatory authority has expressed an opinion about the Company's securities and it is an offence to claim otherwise. This presentation contains "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements are based on the Company's current expectations, estimates and assumptions, and are subject to risks, uncertainties, and other factors that could cause actual results to differ materially. These risks include, without limitation, risks relating to early-stage companies, financing requirements, regulatory approvals, market volatility and reliance on key personnel. Readers should not place undue reliance on forward-looking statements. Except as required by law, the Company undertakes no obligation to update or revise forward-looking information. This presentation also contains market and industry data obtained from third-party sources that are believed to be reliable; however, the Company has not independently verified such data and makes no representation as to its accuracy or completeness. Recipients of this presentation are strictly prohibited from distributing, reproducing, or using it for any purpose other than evaluating a potential investment in the Company.



Identifying & Investing in the Next Generation of Biotech, AI, Robotics, Quantum, and Defence Innovators

Access to innovation through one public entity: LITT - TSXV

- Our unique model enables us to identify and invest early in high-potential biotech, AI, robotics, quantum, and defence technology companies, actively supporting founders with capital, commercialization guidance, and strategic execution support.
- This scalable and transparent approach combines early-stage venture investing with public market expertise, leveraging our established relationships across Silicon Valley, research institutions, and industry networks to help founders accelerate growth, scale responsibly and identify the best companies to invest in that are already public.
- Our seasoned Executive Team combines deep scientific expertise with public market experience, enabling rigorous evaluation of early-stage technologies and hands-on support to help founders navigate commercialization and scale.
- We deploy capital into select public companies aligned with our scientific and commercialization thesis, extending our strategy beyond the private stage.
- We maintain an ETF-style public markets strategy focused on established and emerging innovators in biotech, AI, robotics, quantum, and defence technology, providing investors diversified exposure to high-potential and market-leading companies alongside early-stage opportunities.

Our Approach



FutureGen
INDUSTRIES CORP.

Our Investment Thesis

Identifying & Supporting Early-Stage Innovators



Early Discovery

- We identify high-potential innovators in biotech, AI, robotics, quantum, and defence technologies through strong founder networks, academic relationships, and scientific insight across Silicon Valley and leading research institutions.
- By investing early in founders developing high-potential science and technology, we support them with capital, commercialization expertise, and strategic execution guidance to accelerate development and scale responsibly.



Strategic Investment

- We invest in companies with strong scientific foundations and compelling commercialization potential, providing capital to support development, execution, and responsible scaling.
- Our network includes leaders such as Stanford, McMaster, and University of British Columbia (UBC), along with founders, operators, and innovation circles across Silicon Valley, offering insight into emerging scientific and commercial opportunities.
- We also follow an ETF-style strategy by investing in established public companies that fit our scientific and commercialization thesis, providing investors exposure to sector-leading AI, biotech, robotics, quantum, and defence innovators.



Fueling Growth & Scaling

- We support companies advancing from early development into commercial execution, helping build market traction, expand operations, and pursue disciplined scaling.
- Our involvement includes strategic input, industry and technical relationships, and capital-markets insights that contribute to commercial progress and long-term value creation.



Problem:

Groundbreaking potential is stuck in laboratories

- Early-stage founders struggle, as do investors wanting to access innovation.
- Many high-tech companies face challenges transitioning from research and proof-of-concept, to scalable operations and market investment.
- Until valuations develop, companies often lack capital, market readiness, and key relationships, requiring strategic support to commercialize and scale innovation.
- There is often no structured bridge between scientific innovation and the public markets, limiting commercialization pathways and investor access to emerging technologies.
- As a result, promising technologies are overlooked, limiting public investor access to high-potential innovation in biotech, AI, robotics, quantum, and defence.



Our Solution:

Unlocking breakthrough innovation for public market investors

- FutureGen bridges early-stage innovators and public investors, helping advance transformative technologies toward sustainable commercial growth and scale.
- We bridge the gap by combining scientific understanding with market insight, providing capital, commercialization support, and strategic connections to fuel growth.
- Our scientific and market-driven framework supports both early-stage ventures and a diversified public markets strategy.
- We act with an ETF-style strategy, investing in public companies aligned with our scientific and commercialization thesis and providing investors exposure to sector-leading biotech, AI, robotics, quantum, and defence technology companies
- Our deep networks in Silicon Valley, academia, and capital markets ensure innovation is funded, structured, and scaled for long-term success.

FutureGen Model

How We Operate

Source Deals/Investments:

We tap into world-class innovation ecosystems such as Stanford, McMaster, and UBC, leveraging our network across academia and capital markets to identify promising early-stage ventures in biotech, AI, robotics, quantum, and defence technologies. We also evaluate public market opportunities aligned with our scientific and commercialization thesis through an ETF-style approach, providing investors exposure to sector-leading companies.

Mentoring/Support:

Our seasoned leadership team works closely with founders to accelerate growth. Our unique approach leverages scientific expertise and market know-how to evaluate real potential.

Research/Validate:

Our deep network of trusted scientific advisors, alongside financial and commercial experts, conduct rigorous due diligence to ensure each opportunity has real and defensible IP, market demand and scalable potential. This validation process reduces risk and improves long-term commercialization success.

Scale/Go Public:

Select companies are funded and supported through public-listing pathways or other value-creation milestones, delivering shareholder value and fueling the next cycle of innovation within our portfolio.



Our Target Markets

Biotechnology

The global biotechnology market is estimated at ~USD 1.77T in 2025 and forecast to reach ~USD 5.71T by 2034, growing at a ~13.9% CAGR ¹. Growth is fueled by advances in biologics, cell and gene therapies, synthetic biology, and AI-enabled drug discovery along with bio-manufacturing.

Artificial Intelligence

The global artificial intelligence market is estimated at ~USD 638B in 2025, growing to ~USD 3.68T by 2034 at a ~19.2% CAGR ². Adoption is accelerating through enterprise deployment of foundation and generative models, automation across industries, and expanding compute and data infrastructure.

Defence Technologies


A global market valued at approximately USD 541 billion in 2025 and projected to approach USD 985 billion by 2034 ³. Expansion is driven by modernization programs, increased adoption of AI-enabled systems, cyber warfare capabilities, unmanned and autonomous systems, next-generation platforms, and space-based defence assets.

Robotics

The global robotics market is estimated at ~USD 53B in 2024, projected to reach ~USD 179B by 2033 at a ~16.3% CAGR ⁴. Growth is driven by advances in AI-powered autonomy, industrial automation, healthcare robotics, and sensing systems.

Quantum Technologies

The global quantum computing market is estimated at ~USD 1.7B in 2025, expected to exceed ~USD 4B by 2030 at a ~20.5% CAGR ⁵. Early adoption is emerging across simulation, optimization, cybersecurity, and advanced computing applications.




Source 1: <https://www.biospace.com/article/biotechnology-market-size-to-reach-usd-5-71-trillion-by-2034/>
Source 2: <https://www.precedenceresearch.com/artificial-intelligence-market>
Source 3: <https://www.businesswire.com/news/home/20250716552207/en/defence-Industry-Outlook-Report-2025-2034-AI-and-Cyber-Warfare-Capabilities-Lead-Market-Growth---ResearchAndMarkets.com>
Source 4: <https://www.thebusinessresearchcompany.com/report/robotics-market>
Source 5: <https://finance.yahoo.com/news/global-quantum-computing-market-size-120000228.html>

Biotechnology

The Opportunity

The global biotechnology market is estimated at approximately USD 1.77 trillion in 2025 and is projected to reach USD ~5.71 trillion by 2034, growing at a CAGR of ~13.90%¹.

Biotechnology is scaling across therapeutics, diagnostics, and bio-manufacturing, driven by advances in biologics, gene and cell therapies, synthetic biology, and AI-enabled discovery.



Source 1: <https://www.globenewswire.com/news-release/2025/09/18/3152565/0/en/Biotechnology-Market-Size-Surges-Toward-USD-5-71-Trillion-as-Biologics-Demand-Grows.html>



Biotechnology

Key Growth Drivers ^{1 2}

- Expansion of biologics, cell and gene therapies, and precision medicine
- Rising R&D investment and clinical pipelines across major indications
- Synthetic biology and scaled bio-manufacturing capabilities
- AI-enabled drug discovery and development acceleration

Major Sub-Segments ^{1 2}

- Therapeutic platforms: cell and gene therapy, mRNA, immunotherapies
- Synthetic biology and bio-manufacturing
- Precision diagnostics and tools
- AI-enabled discovery and development software

Source 1: <https://www.mordorintelligence.com/industry-reports/biotechnology-market>


Source 2: <https://www.biospace.com/biotechnology-market-size-to-reach-usd-5-68-trillion-by-2033>

Artificial Intelligence

The Opportunity

The global artificial intelligence market is projected at approximately USD ~638 billion in 2025 and expected to reach USD ~3.68 trillion by 2034, growing at a CAGR of ~19.2%¹.

Adoption is supported by enterprise deployment of foundation and generative models, AI-enabled automation across industries, and expanding compute and data infrastructure.



Source 1: <https://medium.com/thoughts-on-machine-learning/global-ai-market-to-reach-usd-3-68-trillion-by-2034-amidst-widespread-adoption-961aef6376b8>



Artificial Intelligence

Key Growth Drivers ^{1 2}

- Enterprise deployment of generative and foundation models
- Cloud and data-infrastructure scale for AI workloads
- Integration of AI into automation, analytics, and robotics
- Expanding AI applications across healthcare, finance, and industry

Major Sub-Segments ^{1 2}

- Foundation and generative AI platforms
- AI-enabled automation and analytics software
- AI hardware and semiconductor acceleration
- Applied AI across healthcare, financial services, and industrial systems

Source 1: <https://www.imarcgroup.com/artificial-intelligence-market>

Source 2: <https://www.precedenceresearch.com/artificial-intelligence-market>

Robotics


The Opportunity

The global robotics market is estimated at approximately USD 53.2 billion in 2024 and is projected to reach USD 178.7 billion by 2033, representing a CAGR of ~16.35%¹.

Robotics is scaling across industrial automation, logistics, healthcare, precision manufacturing, and autonomous systems as advances in AI, sensing, mobility, and control transform physical-world automation.

Robotics Market Forecast

Size, By Product Type, 2024-2033 (USD Billion)



Source 1: <https://www.imarcgroup.com/robotics-market>



Robotics

Key Growth Drivers ^{1 2}

- Industrial automation and smart manufacturing adoption
- Expansion of logistics and warehouse robotics
- Increasing use of medical and healthcare service robots
- Labor shortages and rising demand for productivity automation
- AI-enabled autonomy, machine vision, sensing, and control systems

Major Sub-Segments ^{1 2}

- Industrial robots and collaborative robots (cobots)
- Warehouse and logistics robotics / autonomous mobile robots
- Medical and healthcare robotics
- Inspection, security, and industrial service robots
- AI-enabled robotic perception, control, and mobility software

Source 1: <https://www.imarcgroup.com/robotics-market>

Source 2: <https://www.mordorintelligence.com/industry-reports/robotics-market>

Quantum Technologies


The Opportunity

The global quantum computing market was valued at approximately USD 1.7 billion in 2025 and is projected to reach over USD 4 billion by 2030 (CAGR \approx 20.5% from 2025-30)¹.

Early commercial applications are emerging in simulation/optimization, machine learning, and other advanced computing domains.



Source 1: <https://www.grandviewresearch.com/industry-analysis/quantum-computing-market>



Quantum Technologies

Key Growth Drivers ^{1 2}

- Increasing enterprise and government R&D investment
- Cloud-based quantum access and hybrid classical-quantum approaches
- High-value use cases in drug discovery, materials science, and optimization
- Ecosystem development through partnerships and platform maturation

Major Sub-Segments ^{1 2}

- Quantum hardware platforms (superconducting, trapped-ion, photonic)
- Quantum software and algorithm development
- Quantum security and cryptography tools
- Quantum cloud services and developer environments

Source 1: <https://www.marketsandmarkets.com/Market-Reports/quantum-computing-market-144888301.html>


Source 2: <https://www.grandviewresearch.com/industry-analysis/quantum-computing-market>

Defence Technologies

The Opportunity

The global defence market is valued at approximately USD 541 billion in 2025 and is projected to reach nearly USD 985 billion by 2034, representing a CAGR of ~6.9%¹.

Growth is being driven by rising defence modernization programs, increased investment in AI-enabled systems, cyber-warfare capabilities, autonomous platforms, and next-generation military technologies¹.



Source 1: <https://www.businesswire.com/news/home/20250716552207/en/defence-Industry-Outlook-Report-2025-2034-AI-and-Cyber-Warfare-Capabilities-Lead-Market-Growth---ResearchAndMarkets.com>



Defence Technologies

Key Growth Drivers ¹

- Rising global defence spending driven by geopolitical tensions and modernization
- Increased adoption of AI-enabled defence systems
- Expansion of cyber-warfare capabilities
- Growth in procurement of unmanned systems and next-generation platforms

Major Sub-Segments ¹

- Defence AI Systems
- Cyber defence & Cyber Warfare
- Unmanned and Autonomous Systems
- Next-Generation Weapons Systems
- Space-Based Defence Assets

Source 1: <https://www.businesswire.com/news/home/20250716552207/en/defence-Industry-Outlook-Report-2025-2034-AI-and-Cyber-Warfare-Capabilities-Lead-Market-Growth---ResearchAndMarkets.com>

World-Class Leadership Team



FutureGen
INDUSTRIES CORP.



CEO Kristian Thorlund

A founder, scientist, leader and public markets operator guiding our innovation-first mission.

- PhD in Data Science and MSc in Statistics & Mathematics, specializing in biostatistics, evidence synthesis, and AI-driven innovation
- Academic appointments at McMaster University and Stanford University, with extensive research collaboration with the Bill & Melinda Gates Foundation
- Proven operator and entrepreneur with multiple successful technology exits, building and scaling analytics and AI-driven companies to acquisition
- Deep exposure across AI, quantum computing, and robotics, particularly in advanced technology and healthcare applications
- Recognized ability to translate complex scientific and technical innovation into commercial execution, strategic growth, and institutional credibility
- Respected across academic, institutional, and capital-markets communities, trusted by leading researchers, founders, and investors
- Published nearly 200 peer-reviewed articles; ranked in the top 1% of researchers globally, with 28,000+ citations (H-index 67)
- Awarded over \$6M in research funding and named by Clarivate (2016, 2018, 2020) as one of the world's most highly cited scientists

Board of Directors

A seasoned executive team with a disciplined approach to building, financing, and scaling breakthrough ventures.



Tyler Lewis, CFO & Director

With a background in accounting, Mr. Lewis has a decade of experience working in the cannabis and nutraceuticals market in various management positions. Tyler sits on the Board of Green Bridge Metals (CSE: GRBM), a Canadian based natural resource exploration company with properties in Minnesota and Ontario.



Sam Shahrokhi, Director

Mr. Shahrokhi's experience reflects strong investment expertise, particularly in early-stage ventures, strengthened by a diversified background in finance and shareholder communications. He has supported numerous publicly traded companies in achieving strategic objectives and enhancing shareholder value. Sam holds an Economics degree with honors from the University of Victoria, with a minor in business finance.



Constantine Carmichel, Director

Mr. Carmichel is a businessman with 20+ years' experience in corporate finance, including consulting private and public companies, spearheading multiple initial public offerings, and facilitating mergers and acquisitions. Constantine received his Bachelor's Degree in Political Science from University of British Columbia.

Our Advantage



What Sets Us Apart

Strategic and Technical Partnership for Founders and Portfolio Companies



Supporting technical founders with strategic partnerships

We work alongside founders building meaningful science and technology, providing strategic insight, commercialization guidance, and capital-markets experience to help accelerate responsible growth.



Access to leading academic and innovation networks

Our relationships across Stanford, McMaster, UBC, and Silicon Valley innovation circles give founders access to world-class scientific expertise, industry talent, and strategic collaboration opportunities.



Experienced operators and investors

Our team brings hands-on experience building and scaling technology companies, offering pragmatic guidance, thoughtful mentorship, and real operating insight to support execution at key inflection points. This expertise has supported a disciplined approach to identifying and assisting high-potential scientific and technology-driven ventures.




Ensuring long-term growth and sustainability

We support companies through development, commercial expansion, and later-stage financing, including preparation for potential public market pathways when appropriate.

We also operate an ETF-style strategy aligned with our scientific and commercialization thesis, offering investors exposure to sector-leading companies alongside our early-stage portfolio.

FutureGen's Innovation Niche

Combining Venture Capital Upside With Public Market Access

Traditional Venture Capital	 FutureGen Model	Public Venture Capital
Multiple term sheets, slow closings, and dilution	Identify and fund early-stage innovators in biotech, AI, robotics, quantum, and defence technologies with strong scientific and commercialization potential.	Retail access to thematic sectors only (e.g. mining / energy etc.)
Founder risk increases with dilution in later rounds (Series B+)	Provide capital, commercialization support, and strategic connections to accelerate growth and prepare for public market pathways where appropriate.	No direct influence on portfolio companies (if you're not lead investor)
Illiquid with 7–10 year lockups	Support founders through growth and potential public transition, with the ability to remain invested as companies scale.	Often passive and disconnected from early-stage innovation
Single-firm dependency / Board control	Combine scientific expertise with capital-markets knowledge to identify and support ventures positioned for long-term success.	Liquidity but limited insight or access to underlying deals
High concentration in few companies per fund	Use a disciplined approach to evaluate public market opportunities aligned with our biotech, AI, robotics, quantum, and defence-technology thesis through an ETF-style strategy, providing investors exposure to sector-leading innovation.	Limited governance and influence options
No option to monetize IP until exit	Help companies grow responsibly, bring innovations to market, and create value through public listings or strategic partnerships when appropriate.	Diversified but without spinout support
Closed to non-institutional investors	Operate with public-company governance discipline while maintaining focus on innovation and execution.	Generally locked into fund timeline or index rebalance

Management has not independently verified third-party data.

Our Deal Sourcing Advantage

Exclusive access to high-potential early-stage companies and founders



1 Academic & Research Ecosystems

Gain early access to technologies and ventures emerging from cutting-edge academic research through strong relationships with leading research institutions like Stanford, McMaster and UBC.



2 Founder & Operator Network

Direct access to experienced innovators, repeat founders, and technical leaders in biotech, AI, robotics, quantum, and defence sectors, delivering high-quality opportunities before they reach broader markets.



3 Industry & Strategic Partners

Collaborations with industry executives, domain experts, and strategic partners that enable early identification of commercially relevant innovation and support thoughtful company formation and scaling.



4 Scientific & Market Insight

Our team's dual expertise supports early recognition of trends, market inflection points, and breakthrough innovations positioned for sustainable, long-term growth and commercial success. We apply this dual-lens approach across biotech, AI, robotics, quantum, and defence technologies.



5 Diligence & Portfolio Selection

Each opportunity is evaluated under our investment policy using a rigorous diligence framework grounded in scientific and commercial assessment, with independent experts engaged when appropriate. We apply this same thesis-driven approach to evaluate select public market opportunities through an ETF-style strategy, providing exposure to sector-leading companies.

Deployed Capital. Expanding Pipeline.

Building a robust portfolio of transformative technologies

As at November 7, 2025

Sector	Company	Status	Amount Invested	Common Shares Held	Mkt Value of Equity	Unrealized Value Change (%)*
Biotech	Onco Innovations (ONCO-CBOE)	Invested	\$31,175	1,500,000	\$2,475,000	7,839%
Biotech	LIR Life Sciences (SKNY-CSE)	Invested	\$16,250	1,000,000	\$1,220,000	7,408%
Aerospace	LUNR Aerospace Corp. (Private going public anticipated 2026)	Invested	\$150,000	1,000,000	-	-
Private Sector Biotech, Ai, Robotics, Quantum, Defence	Evaluating private-sector opportunities	Actively Evaluating	-	-	-	-
Public Market Biotech, Ai, Robotics, Quantum, Defence	NVIDIA (NVDA) – NASDAQ Moderna (MRNA) – NASDAQ Intuitive Surgical (ISRG) – NASDAQ IBM (IBM) – NYSE Lockheed Martin (LMT) – NYSE	Actively Evaluating	-	-	-	-

Unrealized value changes are based on current public market pricing and/or estimated private valuations and are subject to change. These figures are not indicative of realized returns.

Successful Exits

Track record of advancing science- and technology-driven ventures to commercialization and exits

Sector	Company	Total Gain	Percentage Returned
Biotech	Onco-Innovations (ONCO-CBOE)	\$765,065.33	9816%
Biotech	ASEP	\$118,255.57	1139.10%
Biotech	Core One Labs (COOL)	\$167,473.19	83.74%

A smartphone in the foreground displays various financial charts, including a line graph, a pie chart, and a bar chart. The background is a dark blue gradient with circuit-like patterns.

Capital Structure

As at November 8, 2025

TSXV Trading Symbol

LITT

Shares Issued & Outstanding

51,816,219

Warrants

10,285,715

Options

-

Fully Diluted

62,101,934

Market Cap

\$8.8M



FutureGen Highlights

- Unique – our unique investment approach is guided by our team who utilize scientific expertise and market understanding to identify and support early-stage ventures in biotech, AI, robotics, quantum, and defence technologies
- Access – to leading researchers, innovators, advisers and institutional partners from world-class academic institutions across North America
- Growth – we jumpstart innovators to grow and achieve long-term success through flexible access to capital, commercialization support and strategic connections
- Diversified – alongside early-stage ventures, we evaluate select public market opportunities aligned with our scientific and commercialization thesis through an ETF-style strategy, providing investors exposure to sector-leading companies driving innovation
- Focused – on innovation, transparency and responsible growth while maintaining governance standards of a public company
- Disciplined – investment decisions are overseen by FutureGen's Investment Committee & Board, ensuring disciplined governance and transparency
- Demonstrated Success – prior identification and support of early-stage biotech and tech companies including ONCO, ASEP, and COOL



Contact Us

Vancouver, Canada

🌐 FutureGenindustries.com

📞 1 (800) 406-6185

✉ info@futuregenindustries.com

LITT - TSXV

